COSM news

Cosmos Health raised its Q4 2026 U.S. revenue guidance to $15M from its prior $8.2M first orders, driven by rapid subscription growth and expanded marketing. While today's press release indicates this is the most-up-to-date financial outlook, it should not be interpreted as forward-looking guidance …

Cosmos Health has designated 100,000 series B preferred shares for issuance with distinct voting rights and preferences. This move establishes a new class of authorized capital that could affect the voting power of common shareholders.

Cosmos Health Inc.'s Board approved a repurchasing program for up to $5 million of common stock. This signals management's confidence in operational strength and an undervalued stock price.

Cosmos Health posted record Q1 2026 revenue of $17.9M, up 31% YoY, while reducing liabilities by $4.5M and improving stockholders' equity. The company remains near breakeven on adjusted EBITDA as it invests in global expansion, including U.S. market entry.